Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

Ascidian chief scientific officer Robert Bell (L) overlooks research in the company's lab in Boston (courtesy Ascidian) June 3, 2026 07:00 AM EDT DealsCell/Gene Tx Lil­ly strikes As­cid­i­an deal worth up to $1.9B for RNA edit­ing in kid­ney dis­eases Ryan Cross Senior Science Correspondent Last month, As­cid­i­an Ther­a­peu­tics pre­sent­ed the first da­ta sug­gest­ing a new way to fix bro­ken genes may be safe in peo­ple. Now … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER